Democratic leaders of four congressional committees sent letters to major pharmaceutical companies demanding transparency regarding recent drug pricing announcements made in coordination with the Trump administration. The lawmakers questioned whether the agreements would meaningfully lower costs for consumers or primarily benefit the Trump family and administration.
The letters were sent to AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer. They request details on the scope of the agreements, including projected impacts on Medicare, future pricing structures, the TrumpRx platform, and any benefits the companies may receive in return. The members expressed concern that the administration’s announcements lacked transparency and failed to demonstrate actual savings for consumers.
The press release asserts that previous Trump administration actions have not delivered on promises to reduce drug prices and, in some cases, have increased costs. The lawmakers argue that both the administration and pharmaceutical companies appear to be shielding the agreements from public scrutiny and congressional oversight.